Retatrutide Dosage Chart and Schedule
Phase 3, not approved
Weekly GIP, GLP-1 and glucagon agonist from Lilly. Phase 3, not approved; up to 28% weight loss in trials.
Also called: LY3437943, reta, triple G
Regulatory status (US)
Investigational and not approved. Eli Lilly is running the phase 3 TRIUMPH program and plans to file with the FDA in early 2027. It is not on any compounding list, so it cannot be legally compounded, and FDA warning letters in 2026 named retatrutide sold as a "research" product.
What it is
A once-weekly injectable peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. Tirzepatide hits two of those; semaglutide hits one.
Doses used in the phase 3 TRIUMPH trials
| Weeks | Weekly dose | Note |
|---|---|---|
| 1-4 | 2 mg | Starting dose |
| 5-8 | 4 mg | Lowest maintenance arm |
| Then every 4 weeks | up to 9 mg or 12 mg | Highest arms |
From the TRIUMPH-1 design as reported in 2026 (start at 2 mg, step up every 4 weeks to 4, 9 or 12 mg). Exact intermediate steps were not published in the sources we checked. This is a trial protocol, not a label or a recommendation.
Retatrutide reconstitution calculator
Enter your vial and your prescribed dose to see the units on a U-100 syringe. A units chart for every dose step is on the Retatrutide reconstitution calculator page.
What human studies show
- Phase 2 (NEJM 2023, 338 adults, 48 weeks): weekly arms of 1, 4, 8 and 12 mg. The 12 mg arm lost 24.2% of body weight on average vs 2.1% on placebo.
- TRIUMPH-1 (phase 3, 2,339 adults without diabetes, 80 weeks): 4, 9 and 12 mg weekly, starting at 2 mg and stepping up every 4 weeks. Average weight loss was 19.0%, 25.9% and 28.3% (company results presented in 2026).
- TRIUMPH-4 (knee osteoarthritis, 68 weeks): 26.4% at 9 mg and 28.7% at 12 mg vs 2.1% on placebo; 18.2% of people on 12 mg stopped because of side effects.
- Nausea was common, up to about 42% at 12 mg in TRIUMPH-1.
Safety
- No FDA label exists, so there are no approved warnings, contraindications or interaction data.
- Products sold online as "research" retatrutide are unapproved drugs with no checked purity or dose.
- Trial side effects were mostly gastrointestinal and rose with dose.
Compare
Questions
- Is Retatrutide FDA-approved?
- Investigational and not approved. Eli Lilly is running the phase 3 TRIUMPH program and plans to file with the FDA in early 2027. It is not on any compounding list, so it cannot be legally compounded, and FDA warning letters in 2026 named retatrutide sold as a "research" product.
- What dose of Retatrutide has been studied?
- 1-4: 2 mg: Starting dose; 5-8: 4 mg: Lowest maintenance arm; Then every 4 weeks: up to 9 mg or 12 mg: Highest arms. From the TRIUMPH-1 design as reported in 2026 (start at 2 mg, step up every 4 weeks to 4, 9 or 12 mg). Exact intermediate steps were not published in the sources we checked. This is a trial protocol, not a label or a recommendation.
- How many units is my Retatrutide dose?
- Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.
Related
Sources
- Jastreboff et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. NEJM 2023
- AJMC: Retatrutide achieves up to 30.3% average weight loss in phase 3 TRIUMPH-1
- Healio: Retatrutide confers up to 28.7% weight loss in knee osteoarthritis (TRIUMPH-4)
- Epocrates: Retatrutide heads toward FDA filing after positive phase 3 results
- FDA warning letter to TXP Innovations (Tex Peptides), Aug 24, 2026
- FDA 510(k) K212499: BD insulin syringes for U-100 insulin
Last checked 2026-11-16. How we pick and check sources: methodology.